Blue biotech is getting into its stride, as the tools of genomics and high throughput screening are applied to unlock the chemical diversity of the oceans.
PharmaLinks, a business dedicated to commercialising pharmaceutical research, is looking for a development partner for an immunosuppressive cytokine with therapeutic potential in inflammatory diseases including rheumatoid arthritis, asthma, COPD and arteriosclerosis.
How will Imperial College London's newly floated tech-transfer affiliate invest its stock-market millions? After raising the money, now comes the fun part: spending it.
Merlin Biosciences has been under the cloud of an investigation by the UK's Serious Fraud Office. Now founder Chris Evans says the firm is planning new investments.
Biotech start-ups in France and elsewhere in Europe make a unique and important contribution to healthcare. They merit special treatment to help them grow.
Yochai Benkler and Lawrence Lessig are two well-known law professors affiliated with very prestigious US universities, Yale and Stanford, respectively. They are specialised in intellectual property like policemen are specialised in crime: it is their bailiwick but they do not particularly like it.
New approaches are needed for predicting the safe dose of novel drugs that are designed to interact with highly specific human targets because existing preclinical toxicology studies may be inadequate.
The IP battlefield is large and diversified. It goes way beyond highly-publicized battles about patenting genes or semi-conductor designs. A case in point is a lawsuit filed July 14 by Materialise nv, a spin-off of Belgium’s Katholieke Universiteit Leuven, against a Swiss-Swedish company, Nobel Biocare.
You have until the end of the month to tell the EU about your "needs in relation to transnational research cooperation and knowledge transfer between public research organisations".
The European Union’s €54 billion research budget for the next seven years may not be approved in time for the beginning of next year – if Slovenia carries out its threat to oppose the funding of stem cell research.
The technology-transfer unit of Imperial College London, continuing preparations for its stock-market debut on 31 July, said it has completed a £25 million private placement and set a public share price that would value the business at £181 million.
The pressing need for alternative energy sources is driving investment into nanotechnology devices for energy applications such as photovoltaic solar cells.
Norwegian researchers want to commercialise an easy-to-use technology that diagnoses the cause of snoring and measures the effectiveness of treatments.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.